November/December 2016

Although there were not as many new specialty drug approvals in 2016, there were many already-approved specialty medications that received expanded indications.

Advances in the support of patients with HIV include remarkable new pharmaceutical therapies, collaborative care, outstanding patient support, and medication management.

Managing the complex environment of specialty products must be both strategic and tactical if you want to compete.

This year has seen different reactions on the congressional and state policy fronts concerning drug pricing.

Therigy co-founder and CEO Russel Allinson, RPh, MS, discusses technological advances that allows specialty pharmacies to easily provide uniform care to every patient across multiple disease states.

The pharmaceutical industry cherishes the diverse sets of feedback generated among parties operating in specialty pharmacy.

Although the federal government has taken steps to comprehensively regulate outsourcing facilities, many states have been slow to reform their pharmacy laws.

Health care lacks the interoperability needed to utilize all of the data available to influence care decisions and improve outcomes.

Recent prosecutions have heightened the risk for both market share discounts and discounts in lieu of service fees.